Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02597036 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT02597036 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 62 participants.
The verdict
NCT02597036, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety of the study drug known as LY3127804 given as monotherapy and in combination with Ramucirumab for participants with advanced or metastatic solid tumors. The study will also include a safety exploration for the combination of LY3127804 plus ramucirumab and paclitaxel
Interventions
- DRUG Paclitaxel
- DRUG Ramucirumab
- DRUG LY3127804
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2015-11-06 |
| Est. Completion | 2020-05-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02597036
The ClinicalTrials.gov registry entry for NCT02597036 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Paclitaxel is the first listed.
NCT02597036 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02597036 about?
NCT02597036 is a clinical study titled "A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors". The main purpose of this study is to evaluate the safety of the study drug known as LY3127804 given as monotherapy and in combination with Ramucirumab for participants with advanced or metastatic solid tumors. The study will also include a safety exploration for the combination of LY3127804 plus ram...
What is the current status of trial NCT02597036?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2015-11-06. Estimated completion is 2020-05-24.
What interventions are being tested in trial NCT02597036?
The interventions under investigation include: Paclitaxel (DRUG), Ramucirumab (DRUG), LY3127804 (DRUG).
Who is sponsoring clinical trial NCT02597036?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.